ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1302
- Registration Number
- NCT02819635
- Locations
- 🇺🇸
The Vancouver Clinic, INC. PS /ID# 162333, Vancouver, Washington, United States
🇺🇸East View Medical Research, LLC /ID# 171183, Mobile, Alabama, United States
🇺🇸CB Flock Research Corporation /ID# 165980, Mobile, Alabama, United States
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 28
- Registration Number
- NCT02819999
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University Hospital of Cleveland, Cleveland, Ohio, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 51
- Registration Number
- NCT02817594
- Locations
- 🇳🇱
Noordwest Ziekenhuisgroep /ID# 152604, Alkmaar, Netherlands
🇳🇱Maasstad Ziekenhuis /ID# 152592, Rotterdam, Netherlands
🇳🇱Universitair Medisch Centrum Groningen /ID# 152596, Groningen, Netherlands
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
- Conditions
- Bacterial InfectionsMethicillin-Resistant Staphylococcus AureusStaphylococcal Skin Infections
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 199
- Registration Number
- NCT02814916
- Locations
- 🇱🇹
Klaipeda Children's Hospital /ID# 235652, Klaipeda, Lithuania
🇧🇬University Multiprofile Hospital for Active Treatment Deva Maria EOOD Burgas /ID# 235965, Bulgas, Bulgaria
🇧🇬MHAT (Multiprofile Hospital for Active Treatment) /ID# 235539, Kozloduy, Bulgaria
A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)
- Conditions
- Psoriatic Arthritis
- Interventions
- Biological: adalimumab (ADA)
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 246
- Registration Number
- NCT02814175
- Locations
- 🇺🇸
Ochsner Clinic Foundation /ID# 155178, Baton Rouge, Louisiana, United States
🇨🇴Centro de Investigacion en Reumatologia y Especialidades Medicas- CIREEM SAS /ID# 151954, Bogota, Cundinamarca, Colombia
🇵🇷Dr. Ramon L. Ortega-Colon, MD /ID# 152957, Carolina, Puerto Rico
Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 206
- Registration Number
- NCT02808975
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center /ID# 168438, Boston, Massachusetts, United States
🇧🇪UZ Gent /ID# 150906, Gent, Oost-Vlaanderen, Belgium
🇨🇦NewLab Clinical Research Inc. /ID# 151315, St. John's, Newfoundland and Labrador, Canada
Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 522
- Registration Number
- NCT02807402
Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
- Conditions
- Chronic Hepatitis C Virus
- Interventions
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AbbVie
- Registration Number
- NCT02806362
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
- Conditions
- Chronic Hepatitis C
- Interventions
- Behavioral: Patient support program
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2019-10-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 256
- Registration Number
- NCT02803138
- Locations
- 🇮🇱
Ha'Emek Medical Center /ID# 153695, Afula, Israel
🇮🇱Assaf Harofeh Medical Center /ID# 153708, Be'er Ya'akov, Israel
🇮🇱The Edith Wolfson Medical Cent /ID# 153706, Holon, Israel
A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
- Conditions
- Parkinson's Disease (PD)
- Interventions
- Drug: Optimized antiparkinsonian treatmentDrug: Levodopa-Carbidopa Intestinal Gel (LCIG)Device: CADD-Legacy ambulatory infusion pumpDevice: Percutaneous endoscopic gastrostomy tubeDevice: Jejunal extension tube
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 63
- Registration Number
- NCT02799381
- Locations
- 🇫🇮
Oulun yliopistollinen sairaala /ID# 150947, Oulu, Finland
🇮🇹A.O. Univ. Ospedali Riuniti /ID# 150853, Ancona, Marche, Italy
🇮🇹Policlinico Universitario Campus Bio-Medico /ID# 150846, Rome, Lazio, Italy